Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5 mL Under Fasting Conditions
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The study was conducted as an open label, balanced, randomized, two-treatment, two-period,
two-sequence, single- dose, crossover bioavailability study comparing oxcarbazepine 300
mg/5mL oral suspension of OHM Laboratories (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
with Trileptal® 300 mg/5mL oral suspension (containing oxcarbazepine 300 mg/5mL) of Novartis
Pharmaceutical Corporation in healthy, adult, male, human subjects under fasting conditions.